Study #2016-1130
A PHASE I STUDY OF DS-3201B IN SUBJECTS WITH ACUTE MYELOGENOUS LEUKEMIA (AML) OR ACUTE LYMPHOCYTIC LEUKEMIA (ALL)
Study Status
Open
Treatment Agent
DS-3201
Principal Investigator
Naval Daver
Description
The goal of the main clinical research study was to find the highest tolerable dose of DS-3201b that could be given to patients with acute myelogenous leukemia (AML) or acute lymphocytic leukemia (ALL). Researchers also wanted to learn if the highest tolerable dose of DS-3201b could help to control the disease. The goal of this Extension Phase of the clinical research study is to continue to provide DS-3201b to patients who were benefitting from the study drug but the main study closed.
General Information
Disease Group: Malignant neoplasms stated as primary lymphoid haematopoietic
Treatment Agent: DS-3201
Treatment Location: Both at MDACC & and Other Sites
Sponsor: Daiichi Sankyo, Inc
Study Status
IRB Review and Approval Date: 03/29/2017
Recruitment Status: Open
Projected Accrual: 61
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Malignant neoplasms stated as primary lymphoid haematopoietic
Study phase:
Phase I
Physician name:
Naval Daver
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789